MagSense™ HER2 Imaging Agent
HER2‑positive Breast Cancer
Phase 2Active
Key Facts
About Imagion Biosystems
Imagion Biosystems delivers targeted, radiation‑free molecular MRI for earlier, more precise cancer detection.
View full company profileTherapeutic Areas
Other HER2‑positive Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Herceptin (Trastuzumab) Biosimilar | NeuClone | Phase 1 |
| Perjeta (Pertuzumab) Biosimilar | NeuClone | Process Scale‑up |
| P-003 | Panacea Biotec | Phase 3 |
| Trastuzumab Biosimilar | Hetero | Phase 3 |
| Legrand‑Herceptin Biosimilar | Laboratorios Legrand | Commercial |
| AfriMab-1 | Afrigen Biologics | Preclinical |
| Biosimilar Trastuzumab | Biosidus | Commercial |
| Trazher | Innogene Kalbiotech | Commercial |
| MINC‑trastuzumab | Suntec Medical | Preclinical |